Why merger rumours move two shares in opposite directions

When you buy shares in a company, you are making a bet on its future. A merger rumour changes that bet in two very different ways depending on which side of the deal you are sitting on — and the market prices in that difference almost immediately. The August 2026 episode involving AstraZeneca, one of the FTSE 100’s biggest companies, and US pharmaceutical giant Bristol Myers Squibb is one of the clearest real-world illustrations of this principle that you are ever likely to see play out over a single week.

What happened

On the morning of 2 August 2026, the Financial Times reported that AstraZeneca and Bristol Myers Squibb had been in preliminary discussions about a potential merger for several months. The combined company would have been worth close to $400 billion, making it one of the largest corporate deals in history. The story was widely covered and treated seriously by analysts and investors.

By the end of that day, two companies in the same industry had seen their shares move sharply — in opposite directions. AstraZeneca, listed on the London Stock Exchange, fell roughly 9%. Bristol Myers Squibb, listed in New York, rose around 6% in premarket trading. Then, on 5 August, Reuters reported that a senior source close to the matter had confirmed: “There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies.” AstraZeneca’s shares rose around 3–6% in response. Bristol Myers fell back.

The whole episode lasted less than a week. But it contained enough for a complete lesson in how markets process merger news.

Why the potential buyer’s shares fall

Let’s start with AstraZeneca, which would have been the buyer in this scenario. In any merger, the acquiring company almost always has to pay a premium above the target’s current share price to convince existing shareholders to sell. Premiums are typically 20–40% above where the shares were trading before the announcement. That is a lot of extra money — and it comes from the buyer’s pocket, not from thin air.

Here is why that matters to AstraZeneca shareholders. When a company spends a very large amount of money to buy another business, it is spending resources that could otherwise have gone to:

• Paying shareholders a higher dividend
• Buying back its own shares (as HSBC did in August 2026)
• Investing in its own research and new products

Instead, the money goes on buying another company at an inflated price. Investors also worry about integration risk — the practical difficulties of merging two very large businesses that each have thousands of employees, complex supply chains, different cultures, and overlapping products. Many major mergers end up costing more than expected and delivering less value than promised.

On top of all that, AstraZeneca and Bristol Myers Squibb both have very large oncology (cancer treatment) businesses. A combined company would have faced intense scrutiny from competition regulators in the US and Europe, who might have forced the merged entity to sell off parts of the business before approving the deal. That kind of regulatory uncertainty makes investors nervous about whether the deal could even proceed as described.

So when the FT story appeared, AstraZeneca shareholders did a quick mental calculation: this could be very expensive, very complicated, and might not even work. Sell. The share price fell roughly 9%.

Why the potential target’s shares rise

Bristol Myers Squibb shareholders faced a completely different calculation. For them, the news was simple and mostly positive: someone who has a lot of money might be willing to pay a substantial premium to buy the company you own.

This is why, in almost every takeover bid or merger rumour, the target’s shares jump toward the expected takeover price. If Bristol Myers Squibb was trading at, say, $60 per share before the news, and investors believe an acquirer would have to pay around $80 to succeed, the market will price BMS shares somewhere between those two numbers while the deal is uncertain. The closer investors believe a deal is to happening, the closer the price moves to the expected offer.

You can think of this as the market “pricing in” the probability of a deal. If there is a 50% chance of a $80 offer and no deal means the shares return to $60, the rational market price is somewhere around $70. That is a rough model, but it captures the logic.

For more on what happens when a bid is actually agreed, the earlier article on what a takeover does to shares covers the EasyJet example from the same month.

The denial: why uncertainty lifting is good news for the buyer

This is the part that catches many beginners off guard. When Reuters confirmed that there were no merger talks between AstraZeneca and Bristol Myers, AstraZeneca’s shares rose. Surely, if the company was offered the chance to grow into a $400 billion giant and turned it down, that is bad news?

Not from most shareholders’ perspective. Remember why the shares fell in the first place: the risk of overpaying, the complexity of integration, the regulatory uncertainty. The denial removed all of those risks at once. AstraZeneca was confirmed to be staying focused on its own strategy, which — and this is important — was already working very well.

Analysts had noted publicly that they were “perplexed” by the reported merger discussions. AstraZeneca was already growing faster than most large pharmaceutical companies, driven by a strong pipeline of cancer drugs and treatments developed in-house. Jefferies analysts wrote at the time that AstraZeneca was “one company that doesn’t need financial engineering”. For a company that is succeeding on its own strengths, a massive and complicated merger carries more risk than reward.

When the deal was confirmed not to be happening, investors essentially said: good. The shares recovered.

What ‘strategic rationale’ actually means

Every time a merger is announced or rumoured, analysts will immediately ask whether there is a convincing strategic rationale. This simply means: is there a genuine business reason why these two companies are better together than apart?

A strong strategic rationale might look like: a pharmaceutical company with excellent research capabilities buying a smaller firm with a drug it needs to fill a gap in its product range. Or a technology company acquiring a business that gives it access to a market it cannot easily enter on its own.

A weak strategic rationale might look like: a large company buying another large company in the same field, where there is significant product overlap and no clear new market being unlocked. In such cases, the promised “synergies” — cost savings from combining operations — often do not materialise or take years longer than expected to arrive.

In the AstraZeneca case, analysts struggled to see why the deal would be strategically necessary for a company already at the top of its game. That scepticism added to the pressure on the shares when the rumour appeared.

The pattern to remember

This is not an isolated event. It is a consistent pattern in financial markets that plays out with remarkable regularity:

Company role	On merger rumour	On denial
Potential buyer (acquirer)	Shares typically fall	Shares typically recover
Potential target	Shares typically rise toward premium	Shares typically fall back

There are exceptions. If a buyer is known to be a disciplined dealmaker with a strong track record of acquisitions, its shares might hold steady or even rise on news of a potential deal. And occasionally a target company will reject a bid, sending its shares down as the premium disappears. But as a general rule, the pattern above holds more often than not, and it reflects a real and logical transfer of risk.

What this means in the Student Investor Challenge

During the challenge, you may hold shares in large FTSE 100 or S&P 500 companies that appear in merger speculation. Here is what to think about when that happens:

1. Is your company the buyer or the target? The answer tells you which direction the initial market reaction is likely to go.
2. Is the strategic rationale credible? If analysts are sceptical, the buyer’s shares may stay under pressure even if the deal looks unlikely to complete.
3. How much has already been priced in? If the target’s shares have already moved 20% toward the expected offer, much of the good news may already be reflected in the price.
4. What happens if the deal falls through? For target companies, the answer is usually: shares fall back to somewhere near where they started. That is a meaningful risk to hold in your virtual portfolio.

Diversification matters here too. If you have concentrated your portfolio in one sector and a major merger rumour sends several companies in that sector moving sharply, your returns can swing dramatically in a short period. Spreading holdings across different sectors reduces the likelihood that a single piece of corporate news will define your week.

The AstraZeneca episode lasted fewer than five trading days from first report to full denial. In that window, anyone who reacted calmly — understanding why the shares were moving rather than just watching the direction — had an advantage over those trading on panic or excitement alone. That calm understanding is exactly what the challenge is designed to help you build.

FAQ

Why do the potential buyer’s shares usually fall on merger news?

When a company announces it wants to buy another, it typically has to pay a premium above the current share price to convince existing shareholders to sell. That money comes from the buyer. Investors in the buying company worry the price will be too high, or that the distraction of integrating a large business will slow growth. Both concerns push the buyer’s share price down. If the deal falls through, those worries go away — which is why the buyer’s shares often bounce back on a denial.

What is a takeover premium?

A takeover premium is the extra amount a buyer pays above a company’s current share price to persuade shareholders to accept the offer. Premiums are typically between 20% and 40% above the pre-announcement price. When a merger rumour circulates, the target’s share price often jumps toward that expected premium, because investors anticipate that whoever ends up buying will have to pay it.

What does ‘strategic rationale’ mean in a merger?

Strategic rationale is the business logic that explains why two companies are better together than apart. If the rationale is weak or unclear — as analysts felt was the case with a possible AstraZeneca/BMS deal — investors will question whether the merger is worth its cost and complexity. A compelling strategic rationale is essential for any large acquisition to gain market confidence.

Why does a denial sometimes push the acquirer’s shares up sharply?

Because uncertainty is one of the things markets dislike most. When a rumour is circulating but unconfirmed, investors do not know whether to price in the deal risk or not. That uncertainty weighs on the potential buyer’s shares. A firm denial removes the uncertainty entirely, which can feel like genuine relief. If the buyer’s shares had fallen sharply on the rumour, the bounce-back on the denial can be significant as that risk unwinds.